CN107019770B - Composition with weight-losing and blood fat-reducing effects and preparation method and application thereof - Google Patents
Composition with weight-losing and blood fat-reducing effects and preparation method and application thereof Download PDFInfo
- Publication number
- CN107019770B CN107019770B CN201610072616.9A CN201610072616A CN107019770B CN 107019770 B CN107019770 B CN 107019770B CN 201610072616 A CN201610072616 A CN 201610072616A CN 107019770 B CN107019770 B CN 107019770B
- Authority
- CN
- China
- Prior art keywords
- parts
- weight
- composition
- extract
- seed extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 85
- 230000000694 effects Effects 0.000 title claims abstract description 41
- 239000008280 blood Substances 0.000 title claims abstract description 33
- 210000004369 blood Anatomy 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 239000000284 extract Substances 0.000 claims abstract description 109
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 27
- 244000077995 Coix lacryma jobi Species 0.000 claims abstract description 26
- 241000207783 Ipomoea Species 0.000 claims abstract description 26
- KYWSCMDFVARMPN-LCSVLAELSA-N Saikosaponin D Chemical compound O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(C[C@@H](O)[C@]67CO[C@]5([C@@H]6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)CO)O[C@@H]([C@@H]1O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KYWSCMDFVARMPN-LCSVLAELSA-N 0.000 claims abstract description 26
- 229930192014 saikosaponin Natural products 0.000 claims abstract description 26
- 239000008518 lycium barbarum polysaccharide Substances 0.000 claims abstract description 24
- 241000427159 Achyranthes Species 0.000 claims abstract description 22
- 239000002994 raw material Substances 0.000 claims abstract description 22
- 230000001603 reducing effect Effects 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims description 16
- 241000736199 Paeonia Species 0.000 claims description 15
- 241001106477 Paeoniaceae Species 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 238000000227 grinding Methods 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 5
- 230000036541 health Effects 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 claims description 2
- 235000015895 biscuits Nutrition 0.000 claims description 2
- 235000012970 cakes Nutrition 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 abstract description 5
- 230000002588 toxic effect Effects 0.000 abstract description 5
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 22
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 22
- 230000037396 body weight Effects 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 15
- 235000012000 cholesterol Nutrition 0.000 description 11
- 210000001789 adipocyte Anatomy 0.000 description 10
- 238000001035 drying Methods 0.000 description 8
- 150000003626 triacylglycerols Chemical class 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000006870 function Effects 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 238000001514 detection method Methods 0.000 description 6
- 210000000582 semen Anatomy 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 235000019786 weight gain Nutrition 0.000 description 5
- 240000000031 Achyranthes bidentata Species 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 230000004584 weight gain Effects 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 238000010268 HPLC based assay Methods 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 235000014590 basal diet Nutrition 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
- 235000013345 egg yolk Nutrition 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 240000005748 Achyranthes aspera Species 0.000 description 1
- 235000005517 Achyranthes aspera Nutrition 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 201000002451 Overnutrition Diseases 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 235000013666 improved nutrition Nutrition 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000020823 overnutrition Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention particularly relates to a composition with weight-losing and blood fat-reducing effects, and a preparation method and application thereof. The composition comprises the following raw materials: 2-30 parts of saikosaponin, 4-34 parts of red peony root extract, 8-32 parts of coix seed extract, 7-31 parts of achyranthes root extract, 2-25 parts of pharbitis seed extract and 2-22 parts of lycium barbarum polysaccharide; on one hand, the composition fully considers the composition of the raw materials and the proportion of the raw materials to each other, so that the raw materials are mutually matched and act together under the specific proportion, thereby playing the roles of losing weight and reducing blood fat; on the other hand, the composition only comprises six raw materials, has simple composition and lower cost; in addition, the composition has the advantages of obvious weight-losing effect and obvious blood fat reducing effect, small toxic and side effects and high safety.
Description
Technical Field
The invention belongs to the field of medicines, health-care products or foods, and particularly relates to a composition with weight-losing and blood fat-reducing effects, and a preparation method and application thereof.
Background
With the development of economy, the living standard of people is continuously improved, and over nutrition and high-fat food intake cause obesity to some people. Obesity not only brings the trouble of self-posture to people, but also causes the overload of heart function, causes diseases such as coronary heart disease, cerebral apoplexy, cerebral thrombosis, hypertension, hyperlipidemia, hyperglycemia and the like, and endangers the health of people.
Chinese patent document CN104055969A discloses a medicine for fat people to lose weight and for lean people to grow meat, which comprises 68 Chinese medicines of radix bupleuri, red paeony root, achyranthes aspera and the like. However, the above-mentioned traditional Chinese medicine composition has the disadvantages of complex composition, high cost and the like, thereby limiting the application thereof.
Therefore, the research on the novel medicine with the weight-losing effect, which has the advantages of good treatment effect, small toxic and side effect, simple composition and lower cost, has important significance.
Disclosure of Invention
Therefore, the invention provides the composition with the weight-losing effect, which has the advantages of good treatment effect, small toxic and side effect, simple composition and lower cost, and further provides the preparation method and the application thereof.
In order to solve the technical problems, the invention is realized by the following technical scheme:
the invention provides a composition with weight-losing and blood fat-reducing effects, which comprises the following raw materials:
2-30 parts of saikosaponin, 4-34 parts of red peony root extract, 8-32 parts of coix seed extract, 7-30 parts of achyranthes root extract, 2-25 parts of pharbitis seed extract and 2-22 parts of lycium barbarum polysaccharide.
Preferably, in the composition with weight-reducing and blood fat-reducing effects of the present invention, the composition comprises the following raw materials:
6-26 parts of saikosaponin, 8-30 parts of red peony root extract, 12-28 parts of coix seed extract, 11-26 parts of achyranthes root extract, 6-21 parts of pharbitis seed extract and 6-18 parts of lycium barbarum polysaccharide.
Further preferably, in the composition with weight-reducing and blood lipid-lowering effects of the present invention, the composition comprises the following raw materials:
6 parts of saikosaponin, 21 parts of red paeony root extract, 28 parts of coix seed extract, 18 parts of achyranthes root extract, 21 parts of pharbitis seed extract and 6 parts of lycium barbarum polysaccharide; or
15 parts of saikosaponin, 30 parts of red paeony root extract, 12 parts of coix seed extract, 11 parts of achyranthes root extract, 14 parts of pharbitis seed extract and 18 parts of lycium barbarum polysaccharide; or
26 parts of saikosaponin, 8 parts of red peony root extract, 20 parts of coix seed extract, 26 parts of achyranthes root extract, 6 parts of pharbitis seed extract and 14 parts of lycium barbarum polysaccharide; or
20 parts of saikosaponin, 15 parts of red peony root extract, 16 parts of coix seed extract, 22 parts of achyranthes root extract, 17 parts of pharbitis seed extract and 10 parts of lycium barbarum polysaccharide.
Further preferably, in the composition with weight-reducing and blood fat-reducing effects of the invention,
the red peony root extract is prepared by the following method: heating and reflux-extracting dry red paeony roots for 1-3 times, adding 8-12 times of water by weight each time for extracting for 0.5-2 hours, combining extracting solutions, concentrating and drying to obtain the red paeony root extract;
the coix seed extract is prepared by the following steps: taking dried coix seeds, heating, refluxing and extracting for 2-4 times, adding 8-12 times of water by weight each time, extracting for 1-3 hours, combining extracting solutions, concentrating and drying to obtain the coix seed extract;
the achyranthes bidentata extract is prepared by the following method: taking dried achyranthes bidentata, heating, refluxing and extracting for 1-3 times, adding 8-12 times of water by weight each time, extracting for 0.5-2 hours, combining extracting solutions, concentrating and drying to obtain the achyranthes bidentata;
the pharbitis seed extract is prepared by the following method: taking dried pharbitis seed, heating and refluxing for extraction for 2-4 times, adding 8-12 times of water by weight each time for extraction for 1-3 hours, combining the extracting solutions, concentrating and drying to obtain the compound pharbitis seed extract.
Further preferably, in the composition with weight-reducing and blood fat-reducing effects of the invention,
the red peony root extract is prepared by the following method: heating and reflux-extracting dried radix Paeoniae Rubra for 2 times, adding 10 weight times of water for each time for 1 hr, mixing extractive solutions, concentrating, and drying;
the coix seed extract is prepared by the following steps: extracting dried Coicis semen under reflux for 3 times, adding 10 weight times of water for 2 hr, mixing extractive solutions, concentrating, and drying;
the achyranthes bidentata extract is prepared by the following method: heating and reflux-extracting dried Achyranthis radix for 2 times, adding 10 weight times of water each time for 1 hr, mixing extractive solutions, concentrating, and drying;
the pharbitis seed extract is prepared by the following method: heating and reflux-extracting dried semen Pharbitidis for 3 times, adding 10 weight times of water for each time, extracting for 2 hr, mixing extractive solutions, concentrating, and drying.
The invention also provides a preparation method of the composition with the effects of losing weight and reducing blood fat, which comprises the following steps:
respectively taking the saikosaponin, the red paeony root extract, the coix seed extract, the achyranthes root extract, the pharbitis seed extract and the lycium barbarum polysaccharide in parts by weight, grinding and uniformly mixing to obtain the Chinese medicinal composition.
The invention also provides a preparation containing the composition with the functions of losing weight and reducing blood fat or a preparation containing the composition prepared by the preparation method,
the composition is added with conventional auxiliary materials and prepared into clinically acceptable tablets, capsules, powder, mixtures, pills, granules, solutions, syrups, soft extracts, beverages, biscuits, candies or cakes according to a conventional process.
The conventional auxiliary materials are as follows: fillers, disintegrants, lubricants, suspending agents, binders, sweeteners, flavoring agents, preservatives, bases, and the like. The filler comprises: starch, pregelatinized starch, lactose, mannitol, chitin, microcrystalline cellulose, sucrose, etc.; the disintegrating agent comprises: starch, pregelatinized starch, microcrystalline cellulose, sodium carboxymethyl starch, cross-linked polyvinylpyrrolidone, low-substituted hydroxypropylcellulose, cross-linked sodium carboxymethyl cellulose, etc.; the lubricant comprises: magnesium stearate, sodium lauryl sulfate, talc, silica, and the like; the suspending agent comprises: polyvinylpyrrolidone, microcrystalline cellulose, sucrose, agar, hydroxypropyl methylcellulose, and the like; the adhesive comprises starch slurry, polyvinylpyrrolidone, hydroxypropyl methylcellulose, etc.; the sweetener comprises: saccharin sodium, aspartame, sucrose, sodium cyclamate, glycyrrhetinic acid, and the like; the flavoring agent comprises: sweeteners and various essences; the preservative comprises: parabens, benzoic acid, sodium benzoate, sorbic acid and its salts, benzalkonium bromide, chloroacetidine acetate, eucalyptus oil, etc.; the matrix comprises: PEG6000, PEG4000, insect wax, etc.
The invention also provides application of the composition, the composition prepared by the preparation method, or a preparation of the composition in preparation of medicines, health-care products or foods with the weight-losing effect.
The invention also provides application of the composition, the composition prepared by the preparation method, or a preparation of the composition in preparation of medicines, health-care products or foods with the function of reducing blood fat.
The technical scheme of the invention has the following advantages:
(1) the composition of the raw materials and the proportion of the raw materials are fully considered, so that the raw materials are mutually matched and act together in a specific proportion, and the effects of losing weight and reducing blood fat are exerted;
(2) the composition disclosed by the invention not only has a remarkable weight-losing effect and a remarkable blood fat-reducing effect, but also is small in toxic and side effects and high in safety;
(3) the composition provided by the invention only comprises six raw materials, and is simple in composition and low in cost.
Detailed Description
The technical solutions of the present invention will be described clearly and completely below, and it should be apparent that the described embodiments are some, but not all, embodiments of the present invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
In the following examples and experimental examples, saikosaponin (saikosaponin content: 50% or more, HPLC assay, from Spanish grass science and technology Limited liability company) and lycium barbarum polysaccharide (lycium barbarum polysaccharide content: 50% or more, HPLC assay, from Spanish grass science and technology Limited liability company) were added.
Example 1
The composition with the functions of losing weight and reducing blood fat comprises the following raw materials:
6g of saikosaponin, 21g of red paeony root extract, 28g of coix seed extract, 18g of achyranthes root extract, 21g of pharbitis seed extract and 6g of lycium barbarum polysaccharide;
the preparation method of the composition comprises the following steps:
respectively taking the selected weight of saikosaponin, red peony root extract, coix seed extract, achyranthes root extract, pharbitis seed extract and lycium barbarum polysaccharide, grinding and uniformly mixing to obtain the Chinese medicinal composition.
The composition with the effects of losing weight and reducing blood fat is added with conventional auxiliary materials and prepared into tablets according to a conventional process.
Example 2
The composition with the functions of losing weight and reducing blood fat comprises the following raw materials:
15g of saikosaponin, 30g of red paeony root extract, 12g of coix seed extract, 11g of achyranthes root extract, 14g of pharbitis seed extract and 18g of lycium barbarum polysaccharide;
the preparation method of the composition comprises the following steps:
respectively taking the selected weight of saikosaponin, red peony root extract, coix seed extract, achyranthes root extract, pharbitis seed extract and lycium barbarum polysaccharide, grinding and uniformly mixing to obtain the Chinese medicinal composition.
The composition with the effects of losing weight and reducing blood fat is added with conventional auxiliary materials and prepared into tablets according to a conventional process.
Example 3
The composition with the functions of losing weight and reducing blood fat comprises the following raw materials:
26g of saikosaponin, 8g of red paeony root extract, 20g of coix seed extract, 26g of achyranthes root extract, 6g of pharbitis seed extract and 14g of lycium barbarum polysaccharide;
the preparation method of the composition comprises the following steps:
respectively taking the selected weight of saikosaponin, red peony root extract, coix seed extract, achyranthes root extract, pharbitis seed extract and lycium barbarum polysaccharide, grinding and uniformly mixing to obtain the Chinese medicinal composition.
The composition with the functions of losing weight and reducing blood fat is added with conventional auxiliary materials and prepared into capsules according to a conventional process.
Example 4
The composition with the functions of losing weight and reducing blood fat comprises the following raw materials:
20g of saikosaponin, 15g of red peony root extract, 16g of coix seed extract, 22g of achyranthes root extract, 17g of pharbitis seed extract and 10g of lycium barbarum polysaccharide;
the preparation method of the composition comprises the following steps:
respectively taking the selected weight of saikosaponin, red peony root extract, coix seed extract, achyranthes root extract, pharbitis seed extract and lycium barbarum polysaccharide, grinding and uniformly mixing to obtain the Chinese medicinal composition.
The composition with the effects of losing weight and reducing blood fat is prepared into granules by adding conventional auxiliary materials and preparing according to a conventional process.
Experimental example 1Study on weight-reducing action of the composition of the invention
1. Experimental Material
Cholesterol and sodium cholate were purchased from great wall pharmaceutical, Inc. (China, Shanghai).
The feed is commercially available, and the high-fat feed comprises 75% of basal feed, 2% of cholesterol, 0.5% of sodium cholate, 15% of lard and 7.5% of egg yolk.
130 clean-grade 4-week-old male SD rats (provided by Shanghai Ling Chang Biotechnology Co., Ltd.; initial body weight of 150-.
2. Experimental methods
2.1 Experimental groups
120 rats with concentrated body weight were selected from 130 rats and were randomly and equally divided into 12 groups of 10 rats each, which were an experimental group 1-4 group, a control group 1-6 group, a model control group, and a blank control group. The blank control group was fed basal diet, and the other groups were fed high-fat diet.
2.2 methods of administration
Experimental groups 1 to 4 were administered 200mg/kg of the compositions prepared in examples 1 to 4, respectively; the control groups 1-6 are administered with saikosaponin 200mg/kg, radix Paeoniae Rubra extract 200mg/kg, Coicis semen extract 200mg/kg, Achyranthis radix extract 200mg/kg, semen Pharbitidis extract 200mg/kg, and fructus Lycii polysaccharide 200mg/kg respectively.
Each group was administered 1 time/day for 7 weeks.
3. Experimental data detection and processing
3.1 detection index
(1) After 7 weeks of administration, the body weight and weight gain of each group were observed and recorded;
(2) body length (length from nose to anus) was accurately measured under anesthesia at the end of 7 weeks before sacrifice, according to the formula Lee's ═ body weight1/3×103Lee's index was calculated per body length (cm).
3.2 statistical analysis
Data processing was performed using SPSS 20.0 software, and differences between groups were analyzed using one-way anova.
4. Results of the experiment
The results of the experimental data of pre-experimental body weight, post-experimental body weight and Lee's index of each group of rats 7 weeks after administration are shown in table 1.
TABLE 1 Pre-test body weight, post-test body weight and Lee's index of rats in each group: (
n＝10)
# denotes P <0.05 compared to the placebo group, # denotes P <0.01 compared to the placebo group;
represents P <0.01 compared with model control group, represents P <0.05 compared with model control group
As can be seen from Table 1: (1) after the rats are fed for 7 weeks, compared with a blank control group, the weight gain and the Lee's index of the rats in the model control group are significantly different (P is less than 0.05), which indicates that the obesity model is successfully modeled;
(2) the rats in the experimental groups 1-4 showed significant weight loss and significant or very significant difference (P <0.05 or P <0.01) in weight gain and significant decrease in the Lee's index (P <0.05) compared to the model control group, indicating that the compositions prepared in examples 1-4 all were able to significantly reduce weight and the Lee's index;
(3) compared with the model control group, the rats in the control groups 1, 5 and 6 have obviously reduced weight gain and significant difference (P <0.05), and the Lee's index is also reduced to a certain extent but has no significant difference;
(5) the body weight gain and the Lee's index of the rats in the control groups 2, 3 and 4 showed no significant decrease compared to the model control group.
5. Conclusion of the experiment
The raw materials in the composition of the invention are matched and act together in a specific proportion, and the composition has obvious weight-losing effect.
Experimental example 2Research on blood fat reducing effect of composition
1. Experimental Material
Cholesterol and sodium cholate were purchased from great wall pharmaceutical, Inc. (China, Shanghai).
The feed is commercially available, and the high-fat feed comprises 75% of basal feed, 2% of cholesterol, 0.5% of sodium cholate, 15% of lard and 7.5% of egg yolk.
130 clean-grade 4-week-old male SD rats (provided by Shanghai Ling Chang Biotechnology Co., Ltd.; initial body weight of 150-.
2. Experimental methods
2.1 Experimental groups
120 rats with concentrated body weight were selected from 130 rats and were randomly and equally divided into 12 groups of 10 rats each, which were an experimental group 1-4 group, a control group 1-6 group, a model control group, and a blank control group. The blank control group was fed basal diet, and the other groups were fed high-fat diet.
2.2 methods of administration
Experimental groups 1 to 4 were administered 200mg/kg of the compositions prepared in examples 1 to 4, respectively; the control groups 1-6 are administered with saikosaponin 200mg/kg, radix Paeoniae Rubra extract 200mg/kg, Coicis semen extract 200mg/kg, Achyranthis radix extract 200mg/kg, semen Pharbitidis extract 200mg/kg, and fructus Lycii polysaccharide 200mg/kg respectively.
Each group was administered 1 time/day for 7 weeks.
3. Experimental data detection and processing
3.1 detection index
(1) At the end of 7 weeks of administration, the rats were bled via the retroorbital venous plexus and their serum Triglycerides (TG) and Total Cholesterol (TC) were quantitatively determined by enzymatic methods on an automatic biochemical analyzer;
(2) at the end of 7 weeks of administration, fat in the right inguinal region of the abdominal cavity was fixed with 2.5% formalin, and sections were embedded in paraffin for pathological section examination, and the number and size (μm) of adipocytes in 10 fields were randomly selected under a 400-fold optical microscope.
3.2 statistical analysis
Data processing was performed using SPSS 20.0 software, and differences between groups were analyzed using one-way anova.
4. Results of the experiment
The results of experiments on Triglyceride (TG), Total Cholesterol (TC) levels and adipocytes in each group of rats 7 weeks after administration are shown in table 2.
Table 2 Triglyceride (TG), Total Cholesterol (TC) levels and adipocytes (x ± s, n ═ 10) for each group of rats
# indicates P <0.01 in comparison with blank control group, P <0.01 in comparison with model control group, and P <0.05 in comparison with model control group
5. Conclusion of the experiment
As can be seen from Table 2: (1) compared with a blank control group, the Triglyceride (TG), the Total Cholesterol (TC) and the fat cell size of the rats in the model control group are obviously increased (P <0.01), and the fat cell number is obviously reduced (P < 0.01);
(2) compared with the model control group, the rats in the experimental groups 1-4 have obviously reduced Triglyceride (TG), Total Cholesterol (TC) and fat cell size (P <0.01), and the fat cell number is obviously increased (P < 0.01);
(3) compared with the model control group, the rats in the control groups 1, 5 and 6 have significant difference of only indexes (P < 0.05);
(4) triglyceride (TG), Total Cholesterol (TC), size of fat cells, and number of fat cells of rats in the control groups 2, 3, and 4 are equivalent to those in the model control group;
(5) the compositions prepared in examples 1 to 4 were significantly superior in the effect of decreasing the size of Triglyceride (TG), Total Cholesterol (TC), and adipocytes to that of the single drug.
5. Conclusion of the experiment
The raw materials in the composition are matched and act together in a specific ratio, and the composition has a remarkable blood fat reducing effect.
Experimental example 3Study of acute toxicity and safety of the composition of the present invention
1. Laboratory instruments and materials
KM mice (provided by shanghai ling biotechnology limited);
biochemical apparatus (BECKMAN COULTER AU 480).
2. Experimental methods
2.1 Experimental groups
50 healthy KM mice, each half male and female, with a body weight of 15-18g, were randomly divided into 5 groups, each half male and female, 10 mice per group, which were blank control groups and experimental groups 1-4 groups, respectively.
2. Method of administration
Experimental groups 1-4 groups: the composition prepared in examples 1 to 4 was administered to a patient with a fasting of 12 hours before administration, and the composition was administered at maximum concentration, maximum volume, and gavage of 30mL/kg at one time, and finally 10 g/kg.
Blank control group: the stomach was perfused with an equal volume of saline.
Each group was administered for 14 consecutive days.
3. Detection of Experimental data
3.1 detection index
(1) After 14 days of continuous administration, the animals were observed and recorded for weight, intoxication and death;
(2) during the experiment, the poisoned dead animals are dissected to carry out pathological histology examination, whether organs have congestion, bleeding, edema or other changes, and the organs with changes are carried out pathological histology examination;
(3) after the experiment, the surviving mice were subjected to pathological examination and observation (refer to handbook of health food inspection and evaluation technical specification implementation (2003 edition), table 3, of Ministry of health).
TABLE 3 Primary observations in experiments on acute toxicity in rodents
3.2 statistical analysis
Data processing was performed using SPSS 20.0 software, and differences between groups were analyzed using one-way anova.
4. Results of the experiment
The results of the experimental data on the body weights of the mice in each group are shown in table 4.
Table 4 effect on body weight of mice (x ± s, n ═ 10)
| Group number | Body weight (g) before administration | Body weight (g) on day 7 of dosing | Body weight (g) on day 14 of administration |
| Blank control group | 16.3±1.2 | 24.1±1.9 | 34.1±2.5 |
| Experimental group 1 group | 16.4±1.3 | 24.0±1.8 | 32.4±2.7 |
| Experimental group 2 groups | 16.6±1.4 | 22.9±1.7 | 33.4±2.3 |
| Experimental group 3 groups | 16.2±1.2 | 23.6±1.8 | 32.9±2.6 |
| Experimental group 3 groups | 16.5±1.1 | 21.5±2.3 | 31.9±2.2 |
(1) As can be seen from Table 4: compared with a blank control group, the body weight average of the mice of the experimental groups 1-4 is not obviously different;
(2) during the experiment period, the blank control group and the experimental groups 1-4 have no death phenomenon, normal activity, normal hair, no breathing, urination, defecation and glandular secretion abnormality.
5. Conclusion of the experiment
This shows that the compositions prepared in examples 1 to 4 have less toxic and side effects and higher safety due to the mutual matching and combined action of the raw materials in a specific ratio.
From the above, it can be seen from experimental examples 1 to 3 that: (1) according to the composition, the raw materials are matched and act together in a specific ratio, so that the effects of losing weight and reducing blood fat are achieved; (2) the composition disclosed by the invention not only has a remarkable weight-losing effect and a remarkable blood fat-reducing effect, but also is small in toxic and side effects and high in safety.
It should be understood that the above examples are only for clarity of illustration and are not intended to limit the embodiments. Other variations and modifications will be apparent to persons skilled in the art in light of the above description. And are neither required nor exhaustive of all embodiments. And obvious variations or modifications therefrom are within the scope of the invention.
Claims (6)
1. The composition with the effects of losing weight and reducing blood fat is characterized by comprising the following raw materials: 6-26 parts of saikosaponin, 8-30 parts of red peony root extract, 12-28 parts of coix seed extract, 11-26 parts of achyranthes root extract, 6-21 parts of pharbitis seed extract and 6-18 parts of lycium barbarum polysaccharide.
2. The composition with weight-losing and blood fat-reducing effects according to claim 1, wherein the composition is prepared from the following raw materials: 6 parts of saikosaponin, 21 parts of red paeony root extract, 28 parts of coix seed extract, 18 parts of achyranthes root extract, 21 parts of pharbitis seed extract and 6 parts of lycium barbarum polysaccharide; or 15 parts by weight of saikosaponin, 30 parts by weight of red peony root extract, 12 parts by weight of coix seed extract, 11 parts by weight of achyranthes root extract, 14 parts by weight of pharbitis seed extract and 18 parts by weight of lycium barbarum polysaccharide; or 26 parts by weight of saikosaponin, 8 parts by weight of red peony root extract, 20 parts by weight of coix seed extract, 26 parts by weight of achyranthes root extract, 6 parts by weight of pharbitis seed extract and 14 parts by weight of lycium barbarum polysaccharide; or 20 parts of saikosaponin, 15 parts of red peony root extract, 16 parts of coix seed extract, 22 parts of achyranthes root extract, 17 parts of pharbitis seed extract and 10 parts of lycium barbarum polysaccharide.
3. A method for preparing the composition with weight-losing and blood fat-reducing effects according to claim 1 or 2, which comprises the following steps: respectively taking the saikosaponin, the red paeony root extract, the coix seed extract, the achyranthes root extract, the pharbitis seed extract and the lycium barbarum polysaccharide in parts by weight, grinding and uniformly mixing to obtain the Chinese medicinal composition.
4. The preparation comprising the composition with the effects of losing weight and reducing blood fat as claimed in claim 1 or 2 or the preparation comprising the composition prepared by the preparation method as claimed in claim 3 is characterized in that the composition is added with conventional auxiliary materials and prepared into clinically acceptable tablets, capsules, powder, mixture, pills, granules, solutions, syrups, soft extracts, beverages, biscuits, candies or cakes according to the conventional process.
5. Use of the composition of claim 1 or 2, the composition prepared by the preparation method of claim 3, or the preparation of the composition of claim 4 in preparing a medicine, health product or food with weight-reducing effect.
6. Use of the composition of claim 1 or 2, the composition prepared by the preparation method of claim 3, or the preparation of the composition of claim 4 in preparing a medicine, health product or food with blood lipid lowering effect.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610072616.9A CN107019770B (en) | 2016-02-02 | 2016-02-02 | Composition with weight-losing and blood fat-reducing effects and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610072616.9A CN107019770B (en) | 2016-02-02 | 2016-02-02 | Composition with weight-losing and blood fat-reducing effects and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107019770A CN107019770A (en) | 2017-08-08 |
| CN107019770B true CN107019770B (en) | 2020-10-27 |
Family
ID=59524986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610072616.9A Active CN107019770B (en) | 2016-02-02 | 2016-02-02 | Composition with weight-losing and blood fat-reducing effects and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107019770B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109700797B (en) * | 2017-10-25 | 2021-06-15 | 南京葆赫生物技术有限公司 | Weight-losing pharmaceutical composition and preparation method and application thereof |
-
2016
- 2016-02-02 CN CN201610072616.9A patent/CN107019770B/en active Active
Non-Patent Citations (1)
| Title |
|---|
| 气血并治方胶囊治疗颈动脉粥样硬化的临床研究;董国菊等;《世界中西医结合杂志》;20081231;第3卷(第1期);第29-31、47页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107019770A (en) | 2017-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109674958B (en) | Traditional Chinese medicine composition with effect of reducing uric acid and preparation method and application thereof | |
| CN105983015B (en) | A pharmaceutical composition containing silibinin and VE | |
| RU2668135C1 (en) | Pharmaceutical composition for the treatment and prevention of degenerative neurological disorders which comprises, as an active ingredient, a mixed root extract of the tree peony root, the root of dahuric angelica and the root of thorowax or its fraction | |
| JP2019521128A (en) | Perilla extract composition | |
| WO2023146294A1 (en) | Pharmaceutical composition containing paeonia lactiflora extract for preventing or treating chronic obstructive pulmonary disease | |
| KR100699790B1 (en) | Pharmaceutical composition for the prevention and treatment of liver disease comprising a Lonicera caerulea L. var. edulis extract | |
| JP2008069143A (en) | Plant extract for treating rheumatoid arthritis | |
| CN107019770B (en) | Composition with weight-losing and blood fat-reducing effects and preparation method and application thereof | |
| KR20040032920A (en) | Fermentation product of cyptoporus volvatus and its preparation method and use | |
| CN108815218B (en) | Pharmaceutical composition and use thereof | |
| CN107019778B (en) | Composition with weight-losing and blood fat-reducing effects and preparation method and application thereof | |
| CN111407773A (en) | Natural biological anti-inflammatory antibacterial agent | |
| CN109700797B (en) | Weight-losing pharmaceutical composition and preparation method and application thereof | |
| KR20040060808A (en) | Anti-Obesity ingredients from medicinal plants and their composition | |
| CN107019748B (en) | Composition with weight-losing and blood sugar-reducing effects and preparation method and application thereof | |
| CN101804083B (en) | Application of pollen pini and extract thereof in treating inflammatory bowel disease and method for preparing extract | |
| CN107019779B (en) | Composition with weight-losing effect and preparation method and application thereof | |
| CN109700964B (en) | Weight-losing composition and preparation method and application thereof | |
| KR102234860B1 (en) | Composition for prevention and treatment of muscle atrophy comprising lespedeza bicolor extract | |
| CN107875350B (en) | A Chinese medicinal composition for treating diabetes | |
| CN114272295A (en) | Traditional Chinese medicine composition for treating diabetic acromelic gangrene | |
| CN107019730B (en) | Composition with weight-losing effect and preparation method and application thereof | |
| CN106692289B (en) | Medical application of barbat skullcap alcohol extract | |
| CN101607009B (en) | Pharmaceutical composition for treating cold | |
| CN109303790B (en) | Medical application of caper or caper extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |